Effient’s advantage vs Plavix was greater in secondary PCI than in primary PCI, according to a post-hoc analysis of the TRITON-TIMI 38 study conducted by LLY:
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.